美国制药商百时美施贵宝宣布,将以15亿美元现金收购私人控股的细胞疗法开发商Orbital Therapeutics。该交易将扩大集团CAR T细胞免疫疗法产品组合,其中包括Orbital的主要实验候选药物OTX-201,该药物旨在针对自体免疫疾病。
美国制药商百时美施贵宝宣布,将以15亿美元现金收购私人控股的细胞疗法开发商Orbital Therapeutics。该交易将扩大集团CAR T细胞免疫疗法产品组合,其中包括Orbital的主要实验候选药物OTX-201,该药物旨在针对自体免疫疾病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.